drugset
drugset / Trial / NCT03353428

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

NCT03353428 ↗

Phase 1/2 Withdrawn Shenzhen Geno-Immune Medical Institute
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety of lung cancer specific cytotoxic lymphocytes (LC-CTLs). The secondary objectives are to evaluate the rate of successful LC-CTLs generation in vitro and determine the anti-lung cancer efficacy.

Timeline

Start
2017-11-15
Primary completion
2019-01
Completion
2020-12

Outcome

Outcome not reported

Stopped: “combine with NCT03356808”

Drugs

EvaluationDrugModalityDoseRoute
Subject LC-CTLs Cell therapy 100000 cells/kg Intravenous
Subject LC-CTLs Cell therapy 4e+06 cells/kg Intravenous

Indications

non-small cell lung carcinoma